[1] |
Saxena N, Hartman M, Aziz R, et al. Prognostic value of axillary lymph node status after neoadjuvant chemotherapy. Results from a multicentre study[J]. Eur J Cancer,2011,47(8): 1186-1192.
|
[2] |
Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM[J]. Ann Surg Oncol,2010,17(6): 1471-1474.
|
[3] |
Jaffe CC. Measures of response: RECIST, WHO, and new alternatives[J]. J Clin Oncol,2006,24(20): 3245-3251.
|
[4] |
Mazouni C, Peintinger F, Wan-Kau S, et al. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome[J]. J Clin Oncol,2007,25(19): 2650-2655.
|
[5] |
姜军. 现代乳腺外科学[M]. 北京:人民卫生出版社,2014:44-45.
|
[6] |
陈侃,季巧金,周冠年. 乳癌Ⅲ区淋巴结清扫的临床意义[J]. 中华普通外科杂志,2006,21(10): 747-748.
|
[7] |
Chua B, Ung O, Taylor R, et al. Is there a role for axillary dissection for patients with operable breast cancer in this era of conservatism?[J]. ANZ J Surg,2002,72(11): 786-792.
|
[8] |
Yildirim E, Berberoglu U. Lymph node ratio is more valuable than level Ⅲ involvement for prediction of outcome in node-positive breast carcinoma patients[J]. World J Surg,2007,31(2): 276-289.
|
[9] |
Kodama H, Nio Y, Iguchi C, et al. Ten-year follow-up results of a randomised controlled study comparing level-I vs level-Ⅲ axillary lymph node dissection for primary breast cancer[J]. Br J Cancer,2006,95(7): 811-816.
|
[10] |
Fan Z, Li J, Wang T, et al. Level Ⅲ axillary lymph nodes involvement in node positive breast cancer received neoadjuvant chemotherapy[J]. Breast,2013,22(6): 1161-1165.
|
[11] |
Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study[J]. Lancet Oncol,2013,14(7): 609-618.
|
[12] |
Classe JM, Loaec C, Gimbergues P, et al. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study[J]. Breast Cancer Res Treat,2019,173(2): 343-352.
|
[13] |
曹欣华,张亚男,胡浩霖,等. 乳腺癌前哨淋巴结的临床研究进展[J/CD]. 中华乳腺病杂志(电子版),2017,11(2): 109-113.
|
[14] |
Goetz MP, Gradishar WJ, Anderson BO, et al. NCCN guidelines insights: breast cancer, version 3.2018[J]. J Natl Compr Canc Netw,2019,17(2): 118-126.
|
[15] |
Houssami N, Ciatto S, Turner RM, et al. Preoperative ultrasound-guided needle biopsy of axillary nodes in invasive breast cancer: meta-analysis of its accuracy and utility in staging the axilla[J]. Ann Surg,2011,254(2): 243-251.
|
[16] |
韩峰,邹如海,唐军,等. 乳腺区域淋巴结的超声定位显像及临床应用[J/CD]. 中华医学超声杂志(电子版),2010,7(11): 1801-1807.
|
[17] |
Altinyollar H, Dingil G, Berberoglu U. Detection of infraclavicular lymph node metastases using ultrasonography in breast cancer[J]. J Surg Oncol,2005,92(4): 299-303.
|
[18] |
Yun SJ, Sohn YM, Seo M. Risk stratification for axillary lymph node metastases in breast cancer patients: What clinicopathological and radiological factors of primary breast cancer can predict preoperatively axillary lymph node metastases?[J]. Ultrasound Q,2017,33(1): 15-22.
|
[19] |
Yin Y, Zeng K, Wu M, et al. The levels of Ki-67 positive are positively associated with lymph node metastasis in invasive ductal breast cancer[J]. Cell Biochem Biophys,2014,70(2): 1145-1151.
|
[20] |
Yenidunya S, Bayrak R, Haltas H. Predictive value of pathological and immunohistochemical parameters for axillary lymph node metastasis in breast carcinoma[J]. Diagn Pathol,2011,6: 18.
|
[21] |
梁华,付华,权毅. 乳腺癌患者新辅助化疗后腋窝淋巴结转移预测模型的建立[J/CD]. 中华乳腺病杂志(电子版),2019,13(2): 81-86.
|
[22] |
Dillon MF, Advani V, Masterson C, et al. The value of level Ⅲ clearance in patients with axillary and sentinel node positive breast cancer[J]. Ann Surg,2009,249(5): 834-839.
|
[23] |
Joshi S, Noronha J, Hawaldar R, et al. Merits of Level Ⅲ axillary dissection in node-positive breast cancer: a prospective, single-institution study from India[J]. J Glob Oncol,2019,5: 1-8.
|
[24] |
Fowble BL, Einck JP, Kim DN, et al. Role of postmastectomy radiation after neoadjuvant chemotherapy in stage Ⅱ-Ⅲ breast cancer[J]. Int J Radiat Oncol Biol Phys,2012,83(2): 494-503.
|
[25] |
Han S, Kim J, Lee J, et al. Comparison of 6 cycles versus 4 cycles of neoadjuvant epirubicin plus docetaxel chemotherapy in stages Ⅱ and Ⅲ breast cancer[J]. Eur J Surg Oncol,2009,35(6): 583-587.
|
[26] |
Tominaga T, Takashima S, Danno M. Randomized clinical trial comparing level Ⅱ and level Ⅲ axillary node dissection in addition to mastectomy for breast cancer[J]. Br J Surg,2004,91(1): 38-43.
|